Erectile Dysfunction Market Report (2022 to 2030) - Pfizer Inc., Eli Lilly and Company, Sanofi, Auxilium Pharmaceuticals, Inc., Bayer AG and Valenta Pharmaceuticals

Pune, Dec. 01, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global erectile dysfunction market is expected to clock US$ 4.30 billion by 2030 and to grow at a CAGR of 8.3% during the forecast period. Owing to the increasing cases of erectile dysfunction cases due to the global rise in the elderly population. This exclusive information is published by Growth Plus Reports in its report titled “Erectile Dysfunction Market – Global Outlook & Forecast 2022-2030”

Download PDF Brochure of Erectile Dysfunction Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/erectile-dysfunction-market/8005

Growth Drivers

The adoption of a sedentary lifestyle and the stress that goes along with it, the growing geriatric population, and the comorbidity of erectile dysfunction with heart disease and diabetes are a few factors that propel the erectile dysfunction (ED) medicine industry. The likelihood of erectile dysfunction is significantly increased by a sedentary lifestyle, drunkenness, and smoking. Increased acceptability of such detrimental lifestyle choices could spur market expansion.

The global erectile dysfunction market has been analyzed from three perspectives: drug, distribution channel, and region.

Excerpts from ‘By Drug Segmentation’

Based on type, the global erectile dysfunction market is subdivided into:

• Sildenafil
• Tadalafil
• Vardenafil
• Alprostadil
• Avanafil
• Udenafil

The most popular medication used as initial therapy for erectile dysfunction is sildenafil (Viagra). One hour prior to intercourse, sildenafil (Viagra) is most effective when taken on an empty stomach. If you suffer from mild to moderate erectile dysfunction, it remains effective for at least four to five hours. Lupin gained approval from the US Food and Drug Administration (FDA) in March 2019 to market its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg as a generic alternative to Pfizer Inc.'s Viagra Tablets, 25 mg, 50 mg, and 100 mg. So, throughout the course of the projection period, the segment is anticipated to grow due to the success of Viagra (sildenafil citrate) in the treatment of erectile dysfunction.

Excerpts from ‘By Region Segmentation’

Based on region, the global erectile dysfunction market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

During the projected period, it is anticipated that the market for erectile dysfunction medications in Asia Pacific will expand quickly. The introduction of new items has contributed to the region's growth. For instance, iX Biopharma stated in May 2020 that it would provide Wafesil and Silcap in Australia via telemedicine to treat an adult patient with erectile dysfunction.

Browse Detailed Summary of Research Report with TOC: https://growthplusreports.com/report/erectile-dysfunction-market/8005

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global erectile dysfunction market are:

• Pfizer Inc.
• Eli Lilly and Company
• Viatris Specialty LLC
• Petros Pharmaceuticals Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• VIVUS, Inc.
• Auxilium Pharmaceuticals, Inc.
• Valenta Pharmaceuticals
• Vigonvita Life Sciences
• EMS
• RDC Clinical Pty Ltd.
• Futura Medical

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL ERECTILE DYSFUNCTION MARKET - ANALYSIS & FORECAST, BY DRUG
   1. Sildenafil
   2. Tadalafil
   3. Vardenafil
   4. Alprostadil 
   5. Avanafil
   6. Udenafil
6. GLOBAL ERECTILE DYSFUNCTION MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Hospital Pharmacy
   2. Retail Pharmacy
   3. Online Pharmacy

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Directly Purchase Premium Copy of Erectile Dysfunction Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=CA1MxrxwXGnDoq6l4SmpRJ0PKaf4rQBWt537ohND&report_id=8005&license=Single

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.